Month: May 2025

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated Outlines Company’s plans to initiate market expansion study (“POC 2”) into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025 Access the “What This Means” video here THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor “What This Means” segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed...

Brings Total Assets Raised Across Hybrid and Opportunistic Credit Business to $40 Billion NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced it has closed on $8.5 billion in total commitments for the Accord+ strategy, inclusive of $4.8 billion for Accord+ Fund II (“the Fund”) as well as separately managed accounts and related structures. The successful close of the second vintage exceeds internal targets and brings total assets for Apollo’s hybrid credit business to approximately $40 billion. Accord+ II employs an opportunistic strategy focusing on high-conviction investments across the credit spectrum. The Fund is expected to tactically allocate to high quality, top of the capital structure investments across both private corporate credit and asset-backed finance as well as secondary opportunities as...

The industry leader’s Data Security Platform and Managed Data Detection and Response service won awards in four categories for excellence in data security, cloud security, and DSPM MIAMI and SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) — RSA CONFERENCE 2025 – Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, today proudly announced it received four Global Infosec Awards during the RSA Conference 2025. Varonis won the Innovative Service award for its Managed Data Detection and Response. The Varonis Data Security Platform received the Editor’s Choice for Cloud Security, the Market Innovator award for Data-Centric Security, and the Market Innovator award for Data Security Posture Management. The panel of judges recognized Varonis for finding, fixing, and alerting to threats to data across IaaS, SaaS, and hybrid environments...

Research highlights AAV manufacturing optimization via Lexeo’s Sf9-baculovirus process NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, LA. “The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality,” said José Manuel Otero, Chief Technical Officer of Lexeo Therapeutics. “Scientists at Lexeo have optimized a manufacturing platform that can maintain purity and potency while significantly...

Bulldog’s Apparent Lack of Understanding of Tejon’s Business Risks Significant Value Destruction at Tejon Urges Shareholders to Vote “FOR” ALL of Tejon Ranch’s 10 Highly Qualified Director Nominees on the WHITE Proxy Card TEJON RANCH, Calif., May 01, 2025 (GLOBE NEWSWIRE) — Tejon Ranch Co. (NYSE:TRC), (“Tejon” or the “Company”), a diversified real estate development and agribusiness company, today announced that it has mailed a letter to shareholders in connection with its upcoming Annual Meeting of Shareholders (the “Annual Meeting”) to be held on May 13, 2025. The full text of the letter follows: The May 13, 2025, Tejon Ranch Annual Meeting is a few weeks away. You have a critical decision to make regarding the future of your investment. Support Tejon TODAY by voting “FOR” ONLY Tejon’s highly qualified director nominees on the...

SANTA CLARA, Calif., May 01, 2025 (GLOBE NEWSWIRE) — Silvaco Group, Inc. (Nasdaq: SVCO) (“Silvaco” or the “Company”), a provider of TCAD, EDA software and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation, today announced a strategic research and development partnership with Professor Jin Jang and the Advanced Display Research Center (ADRC) at Kyung Hee University (KHU), South Korea. This four-year collaboration, which officially commenced on February 1, 2025, aims to advance display technology innovation through the integration of FTCO™ (Fab Technology Co-Optimization) with AI-driven Digital Twin modeling. Under the partnership, Silvaco will fund Ph.D. students at KHU and closely collaborate with Prof. Jang’s team to provide high-quality measurement data for emerging...

TAMPA, Fla., May 01, 2025 (GLOBE NEWSWIRE) — SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced that it will explore an initiative to allocate up to 10% of future cash flows and cash reserves into cryptocurrencies and precious metals, including Bitcoin (BTC), Solana (SOL), as well as physical gold and silver. “We view that diversifying a portion of our cash management strategy into cryptocurrencies and precious metals may enhance financial resilience and create potential long-term value for our shareholders,” commented Adesh Vora Chairman of SRx Health Solutions. “We believe this strategy will not only protect our capital but also position us at the forefront of a rapidly changing economic environment and will continue to strengthen our balance sheet.” About...

Chapman Becomes Chief Executive Officer of RenasantRenasant CEO Kevin ChapmanTUPELO, Miss., May 01, 2025 (GLOBE NEWSWIRE) — Today, Renasant Corporation (the “Company”) announced that Kevin D. Chapman has officially assumed the role of Chief Executive Officer and President of both the Company and Renasant Bank (the “Bank”). C. Mitchell Waycaster, immediate past Renasant CEO, will continue as Executive Vice Chairman for both the Company and the Bank. As Executive Vice Chairman, Waycaster will continue to be involved in strategic planning, investor relations, mergers and acquisitions, and providing guidance and board level oversight for the Company. “As previously announced with our company’s succession plan, it is with full confidence and great enthusiasm that the Board and I pass the leadership torch to Kevin Chapman...

SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) — Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared the da Vinci Single Port (SP) surgical system for transanal local excision/resection, a form of minimally invasive surgery performed through a natural orifice to avoid abdominal surgical incisions for select procedures. This clearance extends the da Vinci SP’s capabilities in colorectal surgery, building upon procedures previously cleared by the FDA in November 2024, which include transabdominal procedures – low anterior resection, total mesorectal excision, colectomy, abdominoperineal resection, and sigmoidectomy. Intuitive engineered the da Vinci SP system to navigate in narrow...

Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio discusses the positive data from lead program, SENTI-202, recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Watch the “What This Means” segment here SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer participated in a Virtual Investor “What This Means” segment. As part of the segment, Dr. Rajangam discussed the recently announced additional positive preliminary data from a Phase 1 clinical...